What is the best way to test for Herpes Simplex Virus 2 (HSV-2)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testing for HSV-2

For active genital lesions, use nucleic acid amplification testing (NAAT/PCR) from the lesion as your first-line diagnostic test; for asymptomatic individuals or when no lesions are present, use type-specific serological testing with glycoprotein G-based assays on venous blood. 1, 2

Testing Strategy Based on Clinical Presentation

When Active Genital Lesions Are Present

NAAT/PCR is the preferred diagnostic test for detecting HSV-2 from genital ulcers or lesions, with sensitivity and specificity exceeding 90% for most FDA-approved assays. 1 This method offers 11-71% superior sensitivity compared to viral culture and allows simultaneous detection and typing of HSV-1 and HSV-2 in a single reaction. 3

Optimal sampling technique:

  • Collect fluid from intact vesicles or swab the base of ulcers 3
  • For male patients, obtain urethral swabs 3
  • For female patients, use cervical/urethral swabs 3
  • NAAT allows less strict sample transportation conditions compared to viral culture 3

Important caveat: Do not obtain HSV molecular assays in the absence of genital ulcers—due to intermittent viral shedding, swabs from intact skin are not sensitive and will yield false-negative results. 1

If NAAT is unavailable: Viral culture is acceptable as a second-choice diagnostic method, though it has significantly lower sensitivity. 1, 3 If HSV is suspected and culture results are negative, follow up with serologic testing to rule out HSV-2 infection. 1

Avoid these tests: Direct immunofluorescence assay and Tzanck smear lack adequate sensitivity and should not be used for diagnosis. 1, 3

When No Lesions Are Present (Asymptomatic Testing)

Use type-specific serological testing with glycoprotein G-based enzyme immunoassay (EIA) or chemiluminescent immunoassay (CLIA) on venous blood samples. 2 These tests have approximately 97% sensitivity and 98% specificity for detecting HSV-2 antibodies. 2

Do not use NAAT for screening asymptomatic individuals—this test is only appropriate when active lesions are present. 2

Interpreting Serological Test Results

Understanding Index Values

The specificity of HSV-2 serological tests is highly dependent on the index value reported:

  • Index value <0.9: Negative 1
  • Index value 0.9-1.1: Indeterminate 1
  • Index value 1.1-2.9: Positive, but specificity is only 39.8% 1, 4
  • Index value ≥3.0: Positive with improved specificity of 78.6% 1, 4

Critical Pitfall: False-Positive Results

For low positive results (index value <3.0), always confirm with a second test using a different glycoprotein G antigen. 2, 4 False-positive HSV-2 results are particularly common in individuals with HSV-1 infection, especially at low index values. 1, 4 Using the Biokit HSV-2 rapid assay as confirmatory testing improves specificity from 93.2% to 98.7% compared to Western blot. 4

Western blot/immunoblot is the gold standard for HSV serologic testing but has limited availability. 1, 2, 4

Window Period Considerations

A negative result within 12 weeks of potential exposure may represent the "window period" before antibodies develop. 2, 4 HSV-2 IgG antibodies develop within several weeks after infection. 2, 4 If recent acquisition is suspected, repeat testing after 12 weeks. 2, 4

The sensitivity of HSV-2 serologic testing is high at 92%, but false-negatives can occur during this early window period. 1

What a Positive Result Means

A positive HSV-2 IgG antibody test indicates past exposure and ongoing latent infection with HSV-2, with antibodies persisting indefinitely. 2, 4 The test cannot distinguish between recent and long-standing infections. 2, 4

Do not use IgM testing for screening—approximately one-third of patients with recurrent genital herpes caused by HSV-2 have IgM responses, making it unreliable for distinguishing primary from recurrent infection. 2

Who Should Be Tested Serologically

Recommended populations for type-specific HSV-2 serology: 2, 3

  • Pregnant women at risk of acquiring HSV infection close to delivery
  • Men who have sex with men
  • People who are HIV positive
  • Sexual partners of individuals with known genital herpes

Widespread screening of the general asymptomatic population is not recommended. 2, 3 The US Preventive Services Task Force recommends against screening for HSV-2 infection among asymptomatic adolescents and adults. 3

Why HSV-1 vs HSV-2 Typing Matters

Always use assays that differentiate between HSV-1 and HSV-2 to provide accurate prognostic information. 1, 3 HSV-2 causes more frequent recurrences and subclinical viral shedding compared to HSV-1 genital infections. 4, 3 Up to 50% of first-episode genital herpes cases are caused by HSV-1, but recurrences are less frequent with genital HSV-1. 3

Important limitation: HSV-1 serologic assays lack sensitivity (only 70.2% in one study), which can result in false-negative diagnoses. 1 HSV-1 IgG detection has poor specificity and positive predictive value for diagnosing genital ulcer disease and may not be clinically useful in this context. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Screening for Asymptomatic HSV-2 Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnostic Approach for Genital Herpes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Significance of Positive HSV Type 2 IgG Antibody

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.